Spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
as	O
potent	O
anti	O
-	O
breast	B-DS
cancer	I-DS
compounds	O
:	O
Their	O
design	O
,	O
synthesis	O
,	O
biological	O
evaluation	O
and	O
cellular	O
target	O
identification	O

The	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
moiety	O
is	O
present	O
as	O
a	O
core	O
in	O
number	O
of	O
alkaloids	O
with	O
substantial	O
biological	O
activities	O
.	O

Here	O
in	O
we	O
report	O
design	O
and	O
synthesis	O
of	O
a	O
library	O
of	O
compounds	O
bearing	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
motifs	O
that	O
demonstrated	O
exceptional	O
inhibitory	O
activity	O
against	O
the	O
proliferation	O
of	O
MCF	O
-	O
7	O
breast	B-DS
cancer	I-DS
cells	O
.	O

The	O
synthesis	O
involved	O
a	O
one	O
pot	O
Pictet	O
Spengler	O
-	O
Oxidative	O
ring	O
contraction	O
of	O
tryptamine	O
to	O
the	O
desired	O
scaffolds	O
and	O
occurred	O
in	O
1	O
:	O
1	O
THF	O
and	O
water	O
with	O
catalytic	O
trifluoroacetic	O
acid	O
and	O
stoichiometric	O
N	O
-	O
bromosuccinimide	O
as	O
an	O
oxidant	O
.	O

Phenotypic	O
profiling	O
indicated	O
that	O
these	O
molecules	O
induce	O
apoptotic	O
cell	O
death	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Target	O
deconvolution	O
with	O
most	O
potent	O
compound	O
5l	O
from	O
the	O
library	O
,	O
using	O
chemical	O
proteomics	O
indicated	O
histone	B-GP
deacetylase	I-GP
2	I-GP
(	O
HDAC2	B-GP
)	O
and	O
prohibitin	B-GP
2	I-GP
as	O
the	O
potential	O
cellular	O
binding	O
partners	O
.	O

Molecular	O
docking	O
of	O
5l	O
with	O
HDAC2	B-GP
provided	O
insights	O
pertinent	O
to	O
putative	O
binding	O
interactions	O
.	O

Globally	O
,	O
breast	B-DS
cancer	I-DS
is	O
one	O
of	O
the	O
most	O
common	O
cause	O
of	O
fatalities	O
in	O
women	B-OG
.	O

Nearly	O
12	O
%	O
of	O
the	O
world	O
wide	O
women	B-OG
population	O
is	O
affected	O
by	O
this	O
debilitating	O
disease	O
.	O

In	O
2012	O
,	O
25	O
%	O
of	O
cancer	B-DS
diagnosed	O
women	B-OG
suffered	O
from	O
breast	B-DS
cancer	I-DS
.	O

In	O
2008	O
,	O
it	O
inflicted	O
fatalities	O
to	O
nearly	O
0	O
.	O
5	O
million	O
people	O
all	O
over	O
the	O
world1	O
.	O

Treatments	O
for	O
breast	B-DS
cancer	I-DS
involved	O
mono	O
and	O
combination	O
drug	O
therapies	O
,	O
surgical	O
and	O
radiation	O
techniques	O
,	O
novel	O
targeted	O
therapies	O
and	O
cancer	B-DS
vaccines234	O
.	O

Variety	O
of	O
breast	B-DS
cancer	I-DS
drugs	O
such	O
as	O
Tamoxifen	O
™,	O
Letrozole	O
™,	O
Docetaxyl	O
™	O
and	O
etc	O
.	O
are	O
being	O
prescribed	O
to	O
the	O
patients	O
as	O
preventive	O
and	O
curative	O
treatments567	O
.	O

However	O
undue	O
toxicity	O
and	O
side	O
effects	O
in	O
these	O
medicines	O
spoil	O
their	O
efficacy8910	O
.	O

Consequently	O
discovering	O
novel	O
,	O
puissant	O
small	O
molecules	O
as	O
potential	O
anti	O
breast	B-DS
cancer	I-DS
drugs	O
and	O
with	O
better	O
safety	O
profile	O
is	O
the	O
need	O
of	O
the	O
hour	O
.	O

Interestingly	O
natural	O
products	O
provide	O
a	O
healthy	O
source	O
for	O
such	O
compounds	O
.	O

Among	O
variety	O
of	O
natural	O
product	O
scaffolds	O
the	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
scaffold	O
forms	O
the	O
basic	O
architectural	O
motif	O
in	O
a	O
plethora	O
of	O
natural	O
as	O
well	O
as	O
non	O
-	O
natural	O
compounds	O
that	O
demonstrates	O
pronounced	O
anticancer	O
activities	O
.	O

It	O
belonged	O
to	O
a	O
family	O
of	O
natural	O
products	O
that	O
were	O
first	O
isolated	O
from	O
plants	B-OG
Apocynaceae	B-OG
and	O
Rubiacae	B-OG
family11	O
.	O

The	O
essential	O
elements	O
of	O
these	O
class	O
of	O
compounds	O
is	O
a	O
pyrrolidine	O
ring	O
spiro	O
fused	O
at	O
the	O
3rd	O
position	O
of	O
the	O
oxindole	O
moiety	O
with	O
diverse	O
substitution	O
on	O
both	O
the	O
pyrrolidine	O
and	O
oxindole	O
rings	O
.	O

For	O
example	O
Spirotryptostatin	O
A	O
and	O
B	O
,	O
1	O
and	O
2	O
inhibits	O
tubulin	B-GP
polymerization	O
and	O
induces	O
cell	O
cycle	O
inhibition	O
of	O
cancer	B-DS
cells	O
at	O
G2	O
/	O
M	O
phase	O
and	O
spirooxindole	O
MI	O
-	O
5	O
,	O
3	O
,	O
demonstrated	O
novel	O
type	O
of	O
inhibition	O
of	O
p53	B-GP
-	O
MDM2	B-GP
protein	O
-	O
protein	O
interaction	O
that	O
is	O
critical	O
for	O
modulating	O
tumor	B-DS
suppressing	O
ability	O
of	O
the	O
p53	B-GP
-	O
proteins	O
(	O
Fig	O
.	O
1	O
)	O
121314	O
.	O

These	O
interesting	O
therapeutic	O
attributes	O
of	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
scaffolds	O
,	O
make	O
them	O
attractive	O
synthetic	O
targets	O
.	O

There	O
has	O
been	O
quite	O
a	O
few	O
elegant	O
chiral	O
and	O
achiral	O
synthesis	O
for	O
this	O
class	O
of	O
compound15	O
.	O

For	O
example	O
intramolecular	O
Mannich	O
reaction	O
of	O
tryptamine	O
or	O
a	O
tryptophan	O
-	O
derived	O
oxindole	O
and	O
an	O
aldehyde	O
,	O
oxidative	O
ring	O
contraction	O
of	O
tetrahydro	O
-	O
β	O
-	O
carbolines	O
,	O
dipolar	O
cycloaddition	O
reactions	O
of	O
azomethineylides	O
with	O
oxindolylidene	O
3	O
-	O
ylidene	O
acetate	O
and	O
intramolecular	O
Heck	O
reaction	O
followed	O
by	O
trapping	O
of	O
an	O
η3	O
-	O
allylpalladium	O
species	O
by	O
a	O
tethered	O
nitrogen	O
nucleophile16171819	O
.	O

There	O
are	O
also	O
few	O
one	O
-	O
pot	O
synthesis	O
to	O
access	O
this	O
class	O
of	O
compounds	O
,	O
involving	O
cycloaddition	O
strategies2021	O
.	O

Here	O
we	O
report	O
design	O
of	O
a	O
library	O
of	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
as	O
potential	O
anti	O
breast	B-DS
cancer	I-DS
molecule	O
that	O
are	O
synthesized	O
via	O
one	O
pot	O
Pictet	O
Spengler	O
-	O
Oxidative	O
ring	O
contraction	O
strategy	O
of	O
tryptamines	O
mediated	O
by	O
N	O
-	O
bromosuccinimide	O
(	O
NBS	O
)	O
(	O
Fig	O
.	O
2	O
).	O

The	O
compounds	O
exhibited	O
substantial	O
inhibition	O
in	O
MCF	O
-	O
7	O
breast	B-DS
cancer	I-DS
cells	O
where	O
we	O
could	O
identify	O
quite	O
a	O
few	O
analogs	O
with	O
low	O
micromolar	O
EC50	O
values	O
.	O

Phenotypic	O
profiling	O
indicated	O
that	O
these	O
compounds	O
induce	O
cell	O
death	O
through	O
apoptosis	O
(	O
Fig	O
.	O
2	O
).	O

A	O
unique	O
polymer	O
technology	O
based	O
proteomics	O
strategy	O
divulged	O
histone	B-GP
deacetylase	I-GP
2	I-GP
(	O
HDAC2	B-GP
)	O
and	O
prohibitin	B-GP
2	I-GP
as	O
the	O
potential	O
cellular	O
binding	O
partners	O
(	O
Fig	O
.	O
2	O
).	O

Molecular	O
docking	O
of	O
the	O
most	O
active	O
compound	O
in	O
the	O
library	O
with	O
HDAC2	B-GP
revealed	O
putative	O
binding	O
interaction	O
that	O
could	O
be	O
harnessed	O
to	O
achieve	O
more	O
potent	O
molecules	O
through	O
target	O
based	O
approach	O
.	O

Results	O
and	O
Discussion	O

Design	O

In	O
the	O
recent	O
past	O
,	O
we	O
had	O
reported	O
diversity	O
oriented	O
synthesis	O
and	O
phenotypic	O
screening	O
of	O
spiropyrrolindole	O
based	O
potent	O
antibreast	O
cancer	B-DS
compounds	O
4	O
,	O
which	O
exhibited	O
inhibition	O
of	O
proliferation	O
of	O
MCF	O
-	O
7	O
cells	O
with	O
an	O
IC50	O
of	O
~	O
24	O
–	O
500	O
nM	O
(	O
Fig	O
.	O
3	O
)	O
22	O
.	O

Preliminary	O
structure	O
activity	O
relationship	O
(	O
SAR	O
)	O
studies	O
indicated	O
that	O
the	O
aromatic	O
or	O
heteroaromatic	O
functionality	O
on	O
the	O
pyrrole	O
moiety	O
played	O
a	O
crucial	O
role	O
in	O
imparting	O
the	O
inhibitory	O
activity	O
.	O

Next	O
we	O
scanned	O
the	O
literature	O
and	O
could	O
identify	O
several	O
indole	O
derivatives	O
such	O
as	O
Chaetochosins	O
G	O
,	O
Vinorelbine	O
(	O
NVB	O
),	O
Vincristine	O
and	O
Vinblastine	O
to	O
name	O
a	O
few	O
that	O
have	O
exhibited	O
potential	O
activity	O
against	O
breast	B-DS
cancer	I-DS
(	O
Fig	O
.	O
3	O
)	O
23242526	O
.	O

These	O
findings	O
highlighted	O
the	O
importance	O
of	O
spiropyrroloindole	O
framework	O
in	O
breast	B-DS
cancer	I-DS
.	O

Subsequently	O
we	O
conceived	O
a	O
library	O
of	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
5	O
.	O

Taking	O
a	O
cue	O
from	O
the	O
preliminary	O
SAR	O
of	O
4	O
,	O
the	O
design	O
focused	O
on	O
diversifying	O
the	O
aromatic	O
functionality	O
of	O
the	O
pyrrole	O
domain	O
of	O
5	O
(	O
Fig	O
.	O
3	O
).	O

Chemistry	O

After	O
close	O
scrutiny	O
of	O
the	O
existing	O
strategies	O
we	O
realized	O
that	O
the	O
oxidative	O
ring	O
contraction	O
would	O
be	O
most	O
amenable	O
for	O
our	O
purpose	O
as	O
with	O
modification	O
it	O
can	O
provide	O
the	O
compounds	O
in	O
a	O
combinatorial	O
fashion	O
.	O

The	O
original	O
sequence	O
involved	O
Pictet	O
Spengler	O
reaction	O
of	O
tryptamine	O
with	O
appropriate	O
aldehydes	O
to	O
afford	O
tetrahydro	O
-	O
β	O
-	O
carboline	O
,	O
which	O
subsequently	O
undergo	O
oxidative	O
ring	O
contraction	O
in	O
presence	O
of	O
water	O
,	O
appropriate	O
acid	O
and	O
an	O
oxidant	O
to	O
generate	O
the	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
27282930	O
.	O

We	O
envisioned	O
a	O
telescoping	O
synthesis	O
and	O
subsequently	O
remolded	O
the	O
sequence	O
to	O
make	O
it	O
a	O
one	O
pot	O
procedure	O
,	O
where	O
the	O
intermediate	O
tetrahydro	O
-	O
β	O
-	O
carboline	O
need	O
not	O
be	O
isolated	O
.	O

Tryptamine	O
and	O
p	O
-	O
tolualdehyde	O
were	O
used	O
as	O
model	O
substrates	O
.	O

Variety	O
of	O
solvents	O
such	O
as	O
tetrahydrofuran	O
(	O
THF	O
),	O
acetonitrile	O
(	O
ACN	O
),	O
1	O
,	O
4	O
-	O
dioxane	O
,	O
toluene	O
,	O
dichloromethane	O
(	O
DCM	O
),	O
ethylene	O
glycol	O
were	O
used	O
(	O
Table	O
1	O
,	O
entry	O
1	O
–	O
7	O
).	O

All	O
the	O
reactions	O
were	O
started	O
at	O
0	O
°	O
C	O
and	O
were	O
warmed	O
to	O
various	O
temperatures	O
ranging	O
from	O
rt	O
→	O
100	O
°	O
C	O
.	O

In	O
most	O
of	O
the	O
reactions	O
the	O
tetrahydro	O
-	O
β	O
-	O
carboline	O
intermediate	O
4a	O
was	O
isolated	O
along	O
with	O
the	O
desired	O
compound	O
5a	O
.	O

Finally	O
the	O
optimized	O
protocolthat	O
included	O
one	O
equivalent	O
of	O
tryptamine	O
,	O
one	O
equivalent	O
of	O
p	O
-	O
tolualdehyde	O
and	O
1	O
.	O
1	O
equivalent	O
of	O
N	O
-	O
bromosuccinimide	O
in	O
1	O
:	O
1	O
THF	O
and	O
water	O
with	O
catalytic	O
trifluoroacetic	O
acid	O
at	O
0	O
°	O
C	O
→	O
rt	O
afforded	O
the	O
desired	O
compound	O
5a	O
exclusively	O
in	O
81	O
%	O
yield	O
(	O
Table	O
1	O
).	O

With	O
the	O
optimized	O
procedure	O
in	O
hand	O
,	O
next	O
we	O
explored	O
the	O
scope	O
of	O
the	O
reaction	O
with	O
variety	O
of	O
aromatic	O
aldehydes	O
and	O
tryptamine	O
.	O

The	O
reactions	O
were	O
conducted	O
in	O
parallel	O
in	O
a	O
custom	O
made	O
20	O
mL	O
,	O
glass	O
carousal	O
and	O
the	O
compounds	O
were	O
purified	O
using	O
Flash	O
Master	O
Parallel	O
(	O
10	O
channel	O
)	O
Automated	O
Flash	O
Chromatography	O
.	O

The	O
reaction	O
condition	O
was	O
amenable	O
to	O
both	O
electron	O
rich	O
and	O
electron	O
poor	O
aromatic	O
aldehydes	O
,	O
affording	O
the	O
desired	O
compounds	O
5b	O
-	O
5m	O
in	O
45	O
–	O
94	O
%	O
yield	O
(	O
Fig	O
.	O
4	O
).	O

The	O
electron	O
poor	O
aldehydes	O
afforded	O
the	O
desired	O
compounds	O
5b	O
,	O
d	O
-	O
e	O
and	O
5m	O
in	O
relatively	O
lower	O
yields	O
(	O
45	O
–	O
60	O
%)	O
compared	O
to	O
the	O
electron	O
rich	O
variant	O
5a	O
/	O
c	O
and	O
5f	O
-	O
l	O
(	O
73	O
–	O
94	O
%).	O

Interestingly	O
,	O
during	O
the	O
reaction	O
of	O
2	O
,	O
5	O
-	O
trifluoromethyl	O
benzaldehyde	O
,	O
the	O
final	O
product	O
5m	O
was	O
obtained	O
along	O
with	O
the	O
corresponding	O
tetrahydro	O
-	O
β	O
-	O
carboline	O
intermediate	O
in	O
~	O
1	O
:	O
1	O
ratio	O
.	O

This	O
,	O
indicated	O
that	O
during	O
oxidative	O
ring	O
contraction	O
of	O
the	O
corresponding	O
tetrahydro	O
-	O
β	O
-	O
carboline	O
intermediate	O
,	O
the	O
C2	O
-	O
C7	O
bond	O
migration	O
depended	O
on	O
the	O
nature	O
of	O
the	O
substituent	O
on	O
the	O
aromatic	O
ring	O
adjacent	O
to	O
the	O
migrated	O
bond	O
and	O
that	O
electron	O
withdrawing	O
functionalities	O
deter	O
the	O
migration	O
(	O
Fig	O
.	O
4	O
).	O

Finally	O
the	O
versatility	O
of	O
the	O
protocol	O
was	O
further	O
emphasized	O
by	O
the	O
synthesis	O
of	O
the	O
heteroaromatic	O
analogs	O
5n	O
and	O
o	O
in	O
59	O
and	O
64	O
%	O
yield	O
respectively	O
.	O

In	O
vitro	O
screening	O
and	O
phenotypic	O
profiling	O

To	O
assess	O
anti	O
breast	B-DS
cancer	I-DS
potential	O
of	O
our	O
library	O
of	O
compounds	O
we	O
screened	O
them	O
at	O
50	O
μM	O
concentration	O
against	O
MCF	O
-	O
7	O
breast	B-DS
cancer	I-DS
cells	O
using	O
MTT	O
colorimetric	O
cell	O
viability	O
assay	O
(	O
Table	O
2	O
).	O

Etoposide	O
,	O
the	O
standard	O
breast	B-DS
cancer	I-DS
drug	O
was	O
used	O
as	O
a	O
positive	O
control31	O
.	O

From	O
the	O
compounds	O
screened	O
several	O
displayed	O
significant	O
inhibition	O
of	O
the	O
proliferation	O
of	O
MCF	O
-	O
7	O
cells	O
,	O
with	O
EC50	O
values	O
in	O
low	O
micromolar	O
range	O
(	O
Table	O
2	O
).	O

Preliminary	O
structure	O
-	O
activity	O
relationships	O
demonstrate	O
that	O
electron	O
withdrawing	O
groups	O
are	O
tolerated	O
at	O
meta	O
and	O
electron	O
donating	O
groups	O
at	O
ortho	O
and	O
para	O
positions	O
.	O

The	O
monosubstituted	O
analogs	O
are	O
more	O
potent	O
than	O
multiple	O
substituted	O
aromatic	O
ring	O
.	O

The	O
2	O
,	O
5	O
-	O
bistrifluoromethyl	O
-	O
and	O
3	O
,	O
4	O
-	O
bismethoxy	O
-	O
aryl	O
analogs	O
retained	O
very	O
weak	O
activity	O
(	O
25	O
–	O
32	O
%	O
inhibition	O
)	O
whilst	O
the	O
unsubstituted	O
analog	O
5l	O
exhibited	O
best	O
potency	O
with	O
an	O
EC50	O
of	O
3	O
.	O
5	O
μM	O
.	O

It	O
was	O
interesting	O
to	O
observe	O
that	O
three	O
of	O
the	O
most	O
potent	O
compounds	O
5e	O
,	O
i	O
and	O
l	O
from	O
our	O
library	O
did	O
not	O
inhibit	O
the	O
proliferation	O
of	O
healthy	O
mammalian	O
COS	O
-	O
7	O
and	O
MCF10A	O
cell	O
lines	O
.	O

Epithelial	O
cell	O
migration	O
is	O
an	O
important	O
characteristic	O
of	O
cancer	B-DS
cells	O
.	O

In	O
a	O
bid	O
to	O
evaluate	O
if	O
compound	O
5i	O
and	O
l	O
,	O
inhibit	O
cells	O
migration	O
,	O
MCF	O
-	O
7	O
cells	O
were	O
treated	O
with	O
it	O
.	O

The	O
cells	O
were	O
photographed	O
after	O
24	O
hours	O
and	O
the	O
migration	O
distance	O
was	O
measured	O
.	O

The	O
data	O
indicated	O
that	O
both	O
the	O
compounds	O
,	O
indeed	O
inhibit	O
cell	O
migration	O
of	O
MCF	O
-	O
7	O
cells	O
compared	O
to	O
the	O
untreated	O
cells	O
.	O

Again	O
etoposide	O
was	O
used	O
as	O
positive	O
control	O
(	O
refer	O
supplementary	O
information	O
-	O
page	O
75	O
).	O

Further	O
,	O
to	O
determine	O
whether	O
apoptosis	O
(	O
or	O
programmed	O
cell	O
death	O
)	O
was	O
the	O
mechanism	O
of	O
cell	O
death	O
,	O
DNA	O
-	O
ladder	O
assay	O
was	O
used	O
.	O

During	O
apoptosis	O
,	O
fragmentation	O
of	O
nuclear	O
proteins	O
and	O
DNA	O
molecule	O
result	O
in	O
chromatin	O
condensation	O
and	O
formation	O
of	O
apoptotic	O
bodies	O
which	O
is	O
manifested	O
as	O
typical	O
ladder	O
fragmentation	O
pattern	O
when	O
analyzed	O
by	O
gel	O
electrophoresis32	O
.	O

However	O
,	O
at	O
times	O
during	O
this	O
experiment	O
instead	O
of	O
ladder	O
fragmentation	O
pattern	O
,	O
smearing	O
is	O
also	O
observed	O
,	O
which	O
indicates	O
necrosis	O
or	O
killing	O
of	O
cells	O
by	O
autolysis33	O
.	O

Experiments	O
with	O
5i	O
and	O
5l	O
resulted	O
in	O
smearing	O
of	O
DNA	O
fragments	O
thereby	O
indicating	O
that	O
both	O
the	O
compounds	O
induce	O
necrosis	O
to	O
MCF	O
-	O
7	O
cells	O
.	O

No	O
DNA	O
internucleosomal	O
fragmentation	O
was	O
observed	O
in	O
cells	O
treated	O
with	O
0	O
.	O
2	O
%	O
DMSO	O
(	O
vehicle	O
control	O
)	O
(	O
Figure	O
1	O
,	O
supplementary	O
information	O
).	O

Additionally	O
necrosis	O
was	O
also	O
confirmed	O
by	O
Annexin	B-GP
-	O
PI	O
FACS	O
based	O
assay	O
(	O
Figure	O
2	O
–	O
11	O
,	O
supplementary	O
information	O
).	O

Target	O
deconvolution	O

Identifying	O
cellular	O
binding	O
partners	O
from	O
a	O
phenotypic	O
screening	O
is	O
an	O
onerous	O
yet	O
essential	O
task	O
.	O

Recently	O
proteomic	O
tools	O
are	O
harnessed	O
to	O
achieve	O
this	O
.	O

Herein	O
we	O
have	O
identified	O
cellular	O
binding	O
partners	O
of	O
5l	O
(	O
the	O
most	O
active	O
compound	O
in	O
our	O
library	O
against	O
MCF	O
-	O
7	O
)	O
by	O
employing	O
a	O
chemical	O
proteomics	O
method	O
that	O
involved	O
our	O
unique	O
polymer	O
technology34	O
.	O

During	O
the	O
process	O
5l	O
was	O
immobilized	O
on	O
a	O
polymer	O
(	O
based	O
on	O
nitrocellulose	O
)	O
in	O
aqueous	O
buffer	O
condition	O
and	O
was	O
washed	O
several	O
times	O
with	O
1X	O
TBS	O
,	O
phosphate	O
buffer	O
.	O

HPLC	O
-	O
UV	O
based	O
quantification	O
of	O
each	O
buffer	O
wash	O
(	O
refer	O
supplementary	O
information	O
)	O
indicated	O
that	O
43	O
%	O
of	O
5l	O
got	O
retained	O
in	O
the	O
matrix	O
(	O
Fig	O
.	O
5	O
).	O

Next	O
,	O
polymer	O
immobilized	O
5l	O
was	O
incubated	O
with	O
MCF	O
-	O
7	O
cell	O
lysate	O
to	O
facilitate	O
drug	O
-	O
target	O
interaction	O
.	O

After	O
washing	O
with	O
1X	O
TBS	O
,	O
the	O
5l	O
-	O
polymer	O
complex	O
bound	O
proteins	O
were	O
recovered	O
by	O
acetone	O
precipitation	O
,	O
dissolved	O
in	O
1X	O
sample	O
buffer	O
,	O
separated	O
on	O
a	O
4	O
–	O
12	O
%	O
gradient	O
gel	O
and	O
the	O
bands	O
were	O
digested	O
by	O
standard	O
“	O
in	O
-	O
gel	O
”	O
trypsin	B-GP
digestion	O
method35	O
.	O

The	O
target	O
capture	O
experiments	O
involved	O
mass	O
spectrometry	O
analysis	O
of	O
the	O
gel	O
slices	O
in	O
an	O
Agilent	O
1260	O
infinity	O
HPLC	O
-	O
Chip	O
/	O
MS	O
system	O
and	O
ran	O
in	O
triplicates	O
where	O
a	O
total	O
of	O
1838	O
protein	O
in	O
control	O
and	O
2184	O
proteins	O
in	O
5l	O
group	O
were	O
identified	O
.	O

The	O
differential	O
proteins	O
(	O
that	O
are	O
present	O
in	O
5l	O
but	O
not	O
in	O
control	O
group	O
)	O
which	O
were	O
common	O
in	O
all	O
the	O
three	O
experiments	O
were	O
identified	O
as	O
the	O
putative	O
targets	O
and	O
are	O
enlisted	O
in	O
the	O
table	O
below	O
(	O
Table	O
3	O
).	O

Of	O
these	O
seven	O
proteins	O
,	O
Histone	B-GP
deacetylase	I-GP
2	I-GP
(	O
HDAC2	B-GP
)	O
and	O
prohibitin2	B-GP
(	O
Table	O
3	O
,	O
entry	O
1	O
and	O
2	O
)	O
have	O
been	O
well	O
demonstrated	O
in	O
scientific	O
literature	O
on	O
their	O
role	O
in	O
cancer	B-DS
.	O

HDAC2	B-GP
is	O
a	O
histone	B-GP
deacetylase	I-GP
enzyme	O
that	O
is	O
over	O
-	O
expressed	O
in	O
various	O
types	O
of	O
cancer	B-DS
including	O
breast	O
cancer36	O
.	O

Vorinostat	O
,	O
an	O
HDAC	B-GP
inhibitor	O
is	O
an	O
US	O
-	O
FDA	O
approved	O
drug	O
for	O
the	O
treatment	O
of	O
lymphomas37	B-DS
.	O

It	O
is	O
possible	O
that	O
5l	O
exerts	O
its	O
anti	O
-	O
cancer	B-DS
activity	O
by	O
inhibiting	O
HDAC2	B-GP
.	O

Recent	O
studies	O
highlight	O
that	O
prohibitin	B-GP
is	O
involved	O
in	O
estrogen	O
dependent	O
breast	O
cancer38	O
.	O

It	O
is	O
a	O
mitochondrial	O
protein	O
and	O
is	O
considered	O
essential	O
for	O
structural	O
integrity	O
of	O
mitochondrial	O
membrane	O
and	O
is	O
also	O
involved	O
in	O
pro	O
-	O
survival	O
mechanisms	O
.	O

Compounds	O
that	O
bind	O
to	O
Prohibitin	B-GP
-	I-GP
2	I-GP
has	O
been	O
shown	O
to	O
induce	O
apoptosis39	O
.	O

Several	O
other	O
mitochondrial	O
proteins	O
such	O
as	O
NAD	B-GP
(	I-GP
P	I-GP
)	I-GP
transhydrogenase	I-GP
and	O
Alanine	B-GP
-	I-GP
tRNA	I-GP
ligase	I-GP
(	O
Table	O
3	O
,	O
entry	O
5	O
and	O
6	O
)	O
could	O
have	O
possibly	O
co	O
-	O
eluted	O
along	O
with	O
Prohibitin	B-GP
.	O

However	O
,	O
this	O
needs	O
careful	O
interpretation	O
of	O
not	O
losing	O
sight	O
that	O
these	O
proteins	O
have	O
been	O
observed	O
in	O
every	O
experiment	O
as	O
a	O
differential	O
protein	O
and	O
thus	O
could	O
be	O
5l	O
target	O
on	O
its	O
own	O
.	O

Targets	O
such	O
as	O
reticulon	B-GP
-	I-GP
4	I-GP
,	O
Ribosome	B-GP
-	I-GP
binding	I-GP
protein	I-GP
1	I-GP
,	O
t	B-GP
-	I-GP
RNA	I-GP
(	I-GP
cytosine	I-GP
(	I-GP
34	I-GP
)-	I-GP
C	I-GP
(	I-GP
5	I-GP
))-	I-GP
methyltransferase	I-GP
(	O
Table	O
3	O
,	O
entry	O
3	O
,	O
4	O
and	O
7	O
)	O
needs	O
further	O
analysis	O
as	O
there	O
is	O
only	O
a	O
limited	O
literature	O
available	O
on	O
their	O
role	O
in	O
any	O
form	O
of	O
cancer	B-DS
or	O
cellular	O
toxicity	O
.	O

Hence	O
HDAC2	B-GP
and	O
Prohibitin	B-GP
2	I-GP
are	O
considered	O
top	O
priority	O
targets	O
for	O
5l	O
(	O
Table	O
3	O
).	O

Molecular	O
docking	O

Next	O
,	O
we	O
conducted	O
molecular	O
docking	O
of	O
5l	O
with	O
HDAC2	B-GP
(	O
Protein	O
Data	O
Bank	O
[	O
PDB	O
]	O
ID	O
of	O
4LY1	O
,	O
this	O
crystal	O
structure	O
is	O
chosen	O
as	O
it	O
has	O
the	O
best	O
resolution	O
(	O
1	O
.	O
57	O
Å	O
)	O
among	O
all	O
HDAC2	B-GP
crystal	O
structures	O
in	O
PDB	O
)	O
to	O
understand	O
their	O
putative	O
binding	O
interaction	O
.	O

Interestingly	O
,	O
it	O
revealed	O
several	O
bonding	O
and	O
non	O
-	O
bonding	O
interactions	O
that	O
could	O
rationalize	O
HDAC2	B-GP
as	O
the	O
deconvoluted	O
target	O
for	O
5l	O
in	O
MCF	O
-	O
7	O
.	O

There	O
is	O
a	O
hydrogen	O
bond	O
between	O
HIS183	O
residue	O
and	O
5l	O
at	O
a	O
distance	O
of	O
2	O
.	O
23Å	O
.	O

Several	O
hydrophobic	O
interactions	O
were	O
observed	O
between	O
5l	O
and	O
amino	O
acids	O
PHE155	O
,	O
PHE210	O
and	O
LEU276	O
.	O

Finally	O
two	O
pi	O
-	O
stacking	O
between	O
5l	O
and	O
HDAC2	B-GP
further	O
strengthens	O
their	O
binding	O
.	O

The	O
overall	O
binding	O
energy	O
of	O
5l	O
-	O
HDAC2	B-GP
complex	O
is	O
-	O
6	O
.	O
35	O
kcal	O
/	O
mol	O
(	O
Fig	O
.	O
6	O
).	O

Discussion	O

Herein	O
we	O
discussed	O
design	O
of	O
a	O
library	O
of	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
inspired	O
from	O
natural	O
and	O
non	O
-	O
natural	O
products	O
which	O
are	O
efficacious	O
against	O
breast	B-DS
cancer	I-DS
.	O

The	O
library	O
synthesis	O
involved	O
a	O
one	O
pot	O
Pictet	O
Spengler	O
-	O
oxidative	O
ring	O
contraction	O
strategy	O
.	O

In	O
general	O
it	O
is	O
a	O
two	O
-	O
step	O
procedure	O
involving	O
Pictet	O
Spengler	O
reaction	O
between	O
tryptamine	O
and	O
appropriate	O
aldehydes	O
to	O
afford	O
β	O
-	O
carbolines	O
followed	O
by	O
NBS	O
-	O
mediated	O
oxidative	O
ring	O
contraction	O
.	O

After	O
a	O
thorough	O
exploration	O
of	O
reaction	O
conditions	O
we	O
were	O
enabled	O
to	O
telescope	O
these	O
two	O
steps	O
into	O
one	O
,	O
which	O
provided	O
access	O
to	O
these	O
compounds	O
in	O
moderate	O
to	O
excellent	O
yields	O
.	O

Interestingly	O
no	O
aromatic	O
ring	O
brominated	O
product	O
was	O
isolated	O
as	O
the	O
byproduct	O
during	O
the	O
reaction	O
.	O

This	O
further	O
highlights	O
the	O
efficiency	O
of	O
this	O
process	O
.	O

Phenotypic	O
screening	O
against	O
MCF	O
-	O
7	O
revealed	O
several	O
active	O
compounds	O
with	O
EC50	O
in	O
low	O
μmolar	O
range	O
(	O
5e	O
,	O
i	O
and	O
l	O
).	O

Etoposide	O
was	O
used	O
as	O
the	O
+	O
ve	O
control	O
and	O
the	O
activity	O
of	O
the	O
most	O
potent	O
compounds	O
,	O
were	O
comparable	O
to	O
it	O
.	O

Further	O
phenotypic	O
profiling	O
indicated	O
that	O
these	O
compounds	O
induce	O
necrotic	O
cell	O
death	O
to	O
MCF	O
-	O
7	O
.	O

Identifying	O
cellular	O
targets	O
from	O
phenotypes	O
is	O
an	O
essential	O
yet	O
extremely	O
tedious	O
effort	O
.	O

Various	O
strategies	O
such	O
as	O
affinity	O
chromatography	O
,	O
activity	O
based	O
protein	O
profiling	O
,	O
label	O
-	O
free	O
techniques	O
,	O
expression	O
cloning	O
techniques	O
and	O
in	O
silico	O
approaches	O
have	O
been	O
harnessed	O
to	O
achieve	O
this4041424344	O
.	O

Our	O
target	O
deconvolution	O
strategy	O
with	O
the	O
most	O
active	O
compound	O
5l	O
included	O
a	O
unique	O
polymer	O
technology	O
via	O
nitrocellulose	O
based	O
polymer	O
that	O
deciphered	O
HDAC2	B-GP
and	O
Prohibitin	B-GP
2	I-GP
as	O
the	O
potential	O
cellular	O
binding	O
targets	O
in	O
MCF	O
-	O
7	O
.	O

Molecular	O
modelling	O
with	O
HDAC2	B-GP
and	O
5l	O
divulged	O
putative	O
binding	O
interaction	O
.	O

This	O
effort	O
exhibited	O
an	O
efficient	O
early	O
drug	O
discovery	O
process	O
involving	O
phenotypic	O
screening	O
.	O

Conclusion	O

In	O
summary	O
a	O
novel	O
compound	O
5l	O
has	O
been	O
discovered	O
via	O
a	O
facile	O
one	O
pot	O
Pictet	O
Spengler	O
-	O
oxidative	O
ring	O
contraction	O
strategy	O
that	O
exhibited	O
substantial	O
inhibition	O
against	O
MCF	O
-	O
7	O
cells	O
with	O
low	O
μmolar	O
EC50	O
.	O

It	O
belonged	O
to	O
a	O
library	O
of	O
compounds	O
based	O
on	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
motif	O
.	O

The	O
library	O
design	O
was	O
inspired	O
from	O
natural	O
and	O
synthetic	O
products	O
with	O
similar	O
architecture	O
that	O
displayed	O
efficacy	O
against	O
breast	B-DS
cancer	I-DS
cells	O
.	O

Phenotypic	O
profiling	O
indicated	O
that	O
it	O
induces	O
cell	O
death	O
by	O
necrosis	O
pathway	O
.	O

A	O
novel	O
proteomics	O
based	O
target	O
deconvolution	O
strategy	O
divulged	O
HDAC2	B-GP
and	O
prohibit	B-GP
2	I-GP
as	O
putative	O
targets	O
.	O

Interestingly	O
compounds	O
5e	O
,	O
i	O
and	O
l	O
selectively	O
presented	O
deleterious	O
effects	O
on	O
MCF	O
-	O
7	O
and	O
presented	O
little	O
or	O
no	O
effect	O
on	O
the	O
corresponding	O
primary	O
cell	O
line	O
MCF10A	O
.	O

This	O
is	O
not	O
surprising	O
as	O
these	O
two	O
cells	O
are	O
genetically	O
different	O
.	O

Additionally	O
it	O
can	O
also	O
be	O
hypothesized	O
that	O
HDAC2	B-GP
which	O
is	O
the	O
potential	O
target	O
for	O
5l	O
,	O
is	O
over	O
expressed	O
in	O
MCF	O
-	O
7	O
and	O
not	O
in	O
MCF10A	O
.	O

Presently	O
SAR	O
studies	O
involving	O
5l	O
and	O
related	O
analogs	O
,	O
with	O
HDAC2	B-GP
as	O
drug	O
target	O
(	O
for	O
breast	B-DS
cancer	I-DS
)	O
is	O
ongoing	O
in	O
our	O
lab	O
.	O

The	O
results	O
will	O
be	O
reported	O
in	O
due	O
course	O
.	O

Methods	O

Chemical	O
synthesis	O

All	O
reactions	O
were	O
carried	O
out	O
in	O
flame	O
-	O
dried	O
tubes	O
with	O
magnetic	O
stirring	O
.	O

Unless	O
otherwise	O
noted	O
,	O
all	O
experiments	O
were	O
performed	O
under	O
argon	O
atmosphere	O
.	O

All	O
reagents	O
were	O
purchased	O
from	O
Sigma	O
Aldrich	O
,	O
Acros	O
or	O
Alfa	O
Aesar	O
.	O

Solvents	O
were	O
treated	O
with	O
4	O
Å	O
molecular	O
sieves	O
or	O
sodium	O
and	O
distilled	O
prior	O
to	O
use	O
.	O
1H	O
NMR	O
and	O
13C	O
NMR	O
spectra	O
were	O
recorded	O
with	O
tetramethylsilane	O
(	O
TMS	O
)	O
as	O
internal	O
standard	O
at	O
ambient	O
temperature	O
unless	O
otherwise	O
indicated	O
Bruker	O
500	O
MHz	O
for	O
1	O
H	O
NMR	O
and	O
125	O
MHz	O
for	O
13C	O
NMR	O
.	O

Chemical	O
shifts	O
are	O
reported	O
in	O
parts	O
per	O
million	O
(	O
ppm	O
)	O
and	O
coupling	O
constants	O
are	O
reported	O
as	O
Hertz	O
(	O
Hz	O
).	O

Splitting	O
patterns	O
are	O
designated	O
as	O
singlet	O
(	O
s	O
),	O
broad	O
singlet	O
(	O
bs	O
),	O
doublet	O
(	O
d	O
),	O
triplet	O
(	O
t	O
).	O

Splitting	O
patterns	O
that	O
could	O
not	O
be	O
interpreted	O
or	O
easily	O
visualized	O
are	O
designated	O
as	O
multiple	O
(	O
m	O
).	O

The	O
Mass	O
Spectrometry	O
analysis	O
was	O
done	O
on	O
the	O
6540	O
UHD	O
Accurate	O
-	O
Mass	O
Q	O
-	O
TOF	O
LC	O
/	O
MS	O
system	O
(	O
Agilent	O
Technologies	O
)	O
equipped	O
with	O
Agilent	O
1290	O
LC	O
system	O
obtained	O
by	O
the	O
Dept	O
.	O
of	O
Chemistry	O
,	O
School	O
of	O
Natural	O
Sciences	O
,	O
Shiv	O
Nadar	O
University	O
,	O
Uttar	O
Pradesh	O
201314	O
,	O
India	O
.	O

MCF10A	O
was	O
obtained	O
from	O
American	O
Tissue	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
,	O
Bethesda	O
,	O
MD	O
).	O

All	O
cells	O
were	O
grown	O
in	O
a	O
humidified	O
atmosphere	O
at	O
37	O
°	O
C	O
,	O
with	O
5	O
%	O
CO2	O
in	O
air	O
.	O

Cell	O
culture	O
conditions	O

MCF	O
-	O
7	O
cells	O
were	O
maintained	O
as	O
monolayer	O
in	O
25	O
cm2	O
culture	O
flasks	O
(	O
T	O
-	O
25	O
)	O
at	O
37	O
°	O
C	O
in	O
DMEM	O
medium	O
(	O
GIBCO	O
,	O
St	O
.	O
Louis	O
,	O
USA	O
)	O
supplemented	O
with	O
high	O
glucose	O
,	O
L	O
-	O
glutamine	O
,	O
pyridoxine	O
hydrochloride	O
,	O
110	O
mg	O
/	O
L	O
sodium	O
pyruvate	O
,	O
3	O
.	O
7	O
g	O
/	O
L	O
NaHCO3	O
and	O
antibiotics	O
(	O
Penicillin	O
-	O
10	O
,	O
000	O
units	O
/	O
mL	O
,	O
Streptomycin	O
−	O
10	O
,	O
000	O
μg	O
/	O
mL	O
,	O
GIBCO	O
,	O
USA	O
).	O

Growth	O
medium	O
(	O
pH	O
7	O
.	O
4	O
)	O
was	O
prepared	O
by	O
adding	O
5	O
%	O
heat	O
inactivated	O
FBS	O
(	O
Fetal	O
Bovine	O
Serum	O
,	O
GIBCO	O
,	O
USA	O
)	O
and	O
stored	O
at	O
4	O
°	O
C	O
.	O

The	O
medium	O
was	O
changed	O
10	O
–	O
18	O
hrs	O
prior	O
to	O
experiment	O
,	O
and	O
cells	O
were	O
confluent	O
at	O
the	O
time	O
of	O
experimentation	O
.	O

Cells	O
were	O
dislodged	O
from	O
flasks	O
by	O
gentle	O
trypsinization	O
containing	O
0	O
.	O
25	O
%	O
Trypsin	B-GP
.	O

MCF	O
-	O
7	O
cells	O
were	O
regularly	O
sub	O
-	O
cultured	O
thrice	O
a	O
week	O
in	O
a	O
seeding	O
density	O
of	O
40	O
,	O
000	O
–	O
50	O
,	O
000	O
cells	O
/	O
cm2area	O
.	O

Cell	O
confluency	O
=	O
70	O
%	O

Cell	O
Viability	O
Assay	O
(	O
MTT	O
Assay	O
)	O

The	O
MTT	O
colorimetric	O
viability	O
assay	O
was	O
performed	O
to	O
evaluate	O
the	O
anticancer	O
effect	O
of	O
compounds	O
.	O

30	O
,	O
000	O
cells	O
/	O
100	O
μl	O
of	O
media	O
were	O
seeded	O
per	O
well	O
and	O
allowed	O
to	O
stretch	O
and	O
adhere	O
overnight	O
at	O
37	O
°	O
C	O
.	O

Following	O
day	O
media	O
was	O
removed	O
and	O
100	O
μl	O
fresh	O
media	O
was	O
added	O
to	O
the	O
grown	O
cells	O
.	O

Adhered	O
cells	O
were	O
then	O
treated	O
with	O
the	O
compounds	O
5a	O
-	O
m	O
dissolved	O
in	O
DMSO	O
in	O
triplicates	O
at	O
a	O
standard	O
concentration	O
of	O
50	O
μM	O
for	O
48	O
hours	O
.	O

There	O
was	O
one	O
positive	O
and	O
one	O
negative	O
control	O
along	O
with	O
13	O
compounds	O
.	O

The	O
results	O
were	O
measured	O
all	O
in	O
triplicate	O
in	O
45	O
wells	O
of	O
96	O
well	O
plate	O
at	O
each	O
time	O
point	O
.	O

Cytotoxic	O
effect	O
was	O
evaluated	O
using	O
ability	O
of	O
live	O
cells	O
to	O
cleave	O
MTT	O
((	O
3	O
-[	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
]-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
))	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
),	O
into	O
formazan	O
crystals	O
.	O

Post	O
48	O
hours	O
of	O
treatment	O
,	O
10	O
μl	O
of	O
MTT	O
(	O
5	O
mg	O
/	O
ml	O
in	O
PBS	O
)	O
was	O
added	O
to	O
the	O
cells	O
and	O
incubated	O
for	O
4	O
hours	O
in	O
dark	O
at	O
37	O
°	O
C	O
.	O

The	O
violet	O
colored	O
crystals	O
formed	O
were	O
then	O
dissolved	O
in	O
100	O
μl	O
DMSO	O
solvent	O
(	O
Dimethyl	O
Sulfoxide	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

The	O
colorimetric	O
assay	O
was	O
read	O
by	O
a	O
MultiMode	O
Plate	O
Reader	O
(	O
Bio	O
-	O
Rad	O
)	O
at	O
595	O
nm	O
.	O

Percentage	O
of	O
Inhibition	O
of	O
drug	O
was	O
calculated	O
by	O
following	O
formula	O
:	O


Cell	O
Migration	O
assays	O

MCF	O
-	O
7	O
cells	O
were	O
grown	O
to	O
confluence	O
in	O
six	O
-	O
well	O
tissue	O
culture	O
plastic	O
dishes	O
to	O
a	O
density	O
of	O
∼	O
0	O
.	O
2	O
million	O
cells	O
/	O
well	O
.	O

After	O
24	O
hrs	O
of	O
seeding	O
,	O
cells	O
were	O
treated	O
with	O
chemical	O
compounds	O
.	O

The	O
medium	O
was	O
removed	O
and	O
the	O
cells	O
were	O
scratched	O
by	O
200	O
μL	O
pipette	O
micro	O
tip	O
through	O
the	O
center	O
of	O
the	O
plate	O
.	O

The	O
cultures	O
were	O
washed	O
to	O
remove	O
debris	O
and	O
re	O
-	O
cultured	O
with	O
DMEM	O
containing	O
10	O
%	O
FBS	O
for	O
cell	O
migration	O
.	O

The	O
cells	O
were	O
imaged	O
at	O
24	O
hrs	O
and	O
the	O
migrated	O
distance	O
was	O
measured	O
.	O

Migration	O
rate	O
was	O
calculated	O
by	O
counting	O
five	O
to	O
seven	O
fields	O
per	O
image	O
and	O
the	O
results	O
presented	O
as	O
the	O
average	O
of	O
three	O
independent	O
experiments	O
performed	O
over	O
multiple	O
days	O
.	O

DNA	O
fragmentation	O
assay	O

The	O
DMSO	O
(	O
dimethyl	O
sulphoxide	O
)–	O
SDS	O
(	O
sodium	O
dodecyl	O
sulphate	O
)–	O
TE	O
(	O
Tris	O
-	O
EDTA	O
)	O
method	O
:	O
2	O
million	O
MCF	O
-	O
7cells	O
were	O
taken	O
as	O
starting	O
material	O
for	O
DNA	O
isolation	O
.	O

Cells	O
were	O
dislodged	O
with	O
Trypsin	B-GP
-	O
EDTA	O
and	O
washed	O
with	O
1	O
X	O
PBS	O
.	O

DMSO	O
was	O
added	O
directly	O
to	O
the	O
cell	O
pellet	O
(	O
100	O
μl	O
)	O
and	O
mixed	O
well	O
by	O
pipetting	O
.	O

TE	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
with	O
2	O
%	O
SDS	O
was	O
added	O
into	O
the	O
mixture	O
with	O
same	O
volume	O
,	O
followed	O
by	O
pipetting	O
.	O

The	O
solution	O
was	O
centrifuged	O
at	O
3000	O
rpm	O
at	O
4	O
°	O
C	O
and	O
30	O
μL	O
of	O
the	O
supernatant	O
was	O
loaded	O
on	O
agarose	O
gel	O
to	O
check	O
the	O
effect	O
of	O
drugs	O
on	O
DNA	O
molecule	O
.	O

Annexin	B-GP
V	I-GP
/	O
propidium	O
iodide	O
staining	O

The	O
assay	O
is	O
based	O
on	O
the	O
ability	O
of	O
the	O
protein	O
annexin	B-GP
V	I-GP
to	O
bind	O
to	O
phosphatidylserine	O
(	O
PS	O
)	O
exposed	O
on	O
the	O
outer	O
membrane	O
leaflet	O
in	O
apoptotic	O
cells	O
(	O
PS	O
also	O
appears	O
on	O
the	O
necrotic	O
cell	O
surface	O
).	O

The	O
annexin	B-GP
V	I-GP
assay	O
was	O
performed	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
(	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
kit	O
,	O
Alexa	O
Fluor	O
).	O

Briefly	O
,	O
the	O
cells	O
were	O
washed	O
with	O
PBS	O
and	O
suspended	O
in	O
pre	O
-	O
diluted	O
binding	O
buffer	O
.	O

The	O
cell	O
density	O
was	O
adjusted	O
to	O
2	O
million	O
and	O
195	O
μl	O
of	O
cell	O
suspension	O
were	O
mixed	O
with	O
5	O
μl	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
incubated	O
for	O
10	O
min	O
in	O
the	O
dark	O
at	O
room	O
temperature	O
.	O

The	O
cells	O
were	O
washed	O
with	O
binding	O
buffer	O
,	O
re	O
-	O
suspended	O
in	O
195	O
μl	O
binding	O
buffer	O
,	O
counterstained	O
with	O
10	O
μl	O
of	O
the	O
20	O
μg	O
/	O
ml	O
propidium	O
iodide	O
stock	O
(	O
final	O
concentration	O
1	O
μg	O
/	O
ml	O
)	O
and	O
the	O
data	O
were	O
acquired	O
by	O
BD	O
FACS	O
diva	O
7	O
.	O
0	O
at	O
6	O
h	O
,	O
12	O
h	O
and	O
24	O
h	O
.	O

Protein	O
Deconvolution	O

Immobilization	O
of	O
5l	O

5l	O
was	O
provided	O
as	O
a	O
lyophilized	O
powder	O
.	O

A	O
100	O
mM	O
stock	O
of	O
5l	O
was	O
made	O
in	O
DMSO	O
.	O

The	O
stock	O
solution	O
was	O
diluted	O
to	O
215	O
μM	O
in	O
1	O
mM	O
of	O
phosphate	O
buffer	O
in	O
pH	O
6	O
.	O
0	O
and	O
incubated	O
with	O
the	O
matrix	O
for	O
16	O
hrs	O
at	O
room	O
temperature	O
.	O

After	O
incubation	O
,	O
the	O
matrix	O
was	O
washed	O
five	O
times	O
with	O
Phosphate	O
buffer	O
.	O

The	O
amount	O
of	O
molecule	O
in	O
the	O
phosphate	O
buffer	O
wash	O
was	O
quantified	O
by	O
HPLC	O
-	O
UV	O
based	O
method	O
and	O
amount	O
of	O
molecule	O
retained	O
on	O
the	O
matrix	O
was	O
calculated	O
.	O

Affinity	O
enrichment	O
of	O
target	O
proteins	O
on	O
5l	O
immobilized	O
matrix	O

Cell	O
lysates	O
were	O
prepared	O
in	O
RIPA	O
buffer	O
and	O
protein	O
concentration	O
was	O
determined	O
by	O
Bradford	O
method	O
.	O

Cell	O
lysate	O
was	O
diluted	O
with	O
1X	O
TBS	O
to	O
a	O
concentration	O
of	O
1	O
mg	O
/	O
ml	O
.	O

The	O
5l	O
immobilized	O
matrix	O
was	O
incubated	O
with	O
2	O
ml	O
of	O
cell	O
lysate	O
for	O
2	O
min	O
with	O
mild	O
shaking	O
.	O

The	O
matrix	O
was	O
washed	O
with	O
1X	O
TBS	O
to	O
remove	O
unbound	O
proteins	O
and	O
to	O
reduce	O
non	O
-	O
specific	O
interactions	O
.	O

The	O
molecule	O
bound	O
proteins	O
were	O
then	O
recovered	O
by	O
acetone	O
precipitation	O
and	O
was	O
dissolved	O
in	O
1X	O
sample	O
buffer	O
.	O

Proteins	O
were	O
separated	O
on	O
a	O
4	O
–	O
12	O
%	O
gradient	O
gel	O
and	O
bands	O
were	O
digested	O
by	O
standard	O
“	O
in	O
-	O
gel	O
”	O
trypsin	B-GP
digestion	O
methods	O
.	O

Mass	O
spectrometry	O
analysis	O
of	O
proteins	O

Protein	O
Reduction	O
,	O
Alkylation	O
and	O
Digestion	O

Clearly	O
identified	O
gel	O
-	O
bands	O
were	O
cut	O
in	O
typical	O
size	O
of	O
1	O
mm	O
band	O
from	O
the	O
gel	O
and	O
placed	O
in	O
1	O
.	O
5	O
ml	O
tubes	O
.	O

Gel	O
slices	O
were	O
washed	O
once	O
with	O
distil	O
water	O
and	O
then	O
twice	O
,	O
with	O
100	O
μL	O
of	O
100	O
mM	O
ABC	O
/	O
50	O
%	O
acetonitrile	O
(	O
ACN	O
)	O
solution	O
by	O
placing	O
the	O
bands	O
in	O
each	O
respective	O
solution	O
at	O
room	O
-	O
temperature	O
for	O
30	O
minutes	O
.	O

After	O
discarding	O
the	O
last	O
wash	O
gel	O
-	O
slices	O
were	O
incubated	O
with	O
50	O
μL	O
of	O
10	O
mM	O
DTT	O
at	O
56	O
°	O
C	O
for	O
10	O
minutes	O
in	O
a	O
dry	O
bath	O
.	O

Tubes	O
were	O
then	O
cooled	O
and	O
then	O
gel	O
-	O
slices	O
were	O
incubated	O
with	O
50	O
μL	O
of	O
100	O
mM	O
IAA	O
at	O
37	O
°	O
C	O
for	O
30	O
minutes	O
.	O

IAA	O
solution	O
was	O
removed	O
and	O
gel	O
slices	O
were	O
rinsed	O
by	O
incubating	O
it	O
with	O
100	O
mM	O
ABC	O
/	O
50	O
%	O
ACN	O
at	O
37	O
°	O
C	O
for	O
15	O
minutes	O
.	O

Rinse	O
solution	O
was	O
removed	O
and	O
gel	O
-	O
slices	O
were	O
dehydrated	O
by	O
incubating	O
them	O
with	O
100	O
μl	O
of	O
100	O
%	O
ACN	O
for	O
10	O
minutes	O
.	O

ACN	O
was	O
removed	O
and	O
gel	O
-	O
slices	O
were	O
dried	O
using	O
a	O
Speed	O
Vac	O
for	O
45	O
–	O
60	O
minutes	O
at	O
room	O
temperature	O
.	O

Gel	O
-	O
slices	O
were	O
then	O
incubated	O
with	O
20	O
–	O
30	O
μl	O
of	O
20	O
μg	O
/	O
ml	O
trypsin	B-GP
solution	O
for	O
an	O
hour	O
at	O
room	O
temperature	O
.	O

50	O
μl	O
of	O
50	O
mM	O
ABC	O
was	O
added	O
to	O
the	O
gel	O
-	O
slices	O
and	O
completely	O
covered	O
tubes	O
were	O
placed	O
at	O
37	O
°	O
C	O
for	O
12	O
hours	O
for	O
maximum	O
trypsin	B-GP
digestion	O
of	O
the	O
protein	O
.	O

Gel	O
-	O
slices	O
were	O
then	O
incubated	O
with	O
150	O
μl	O
of	O
HPLC	O
water	O
for	O
10	O
minutes	O
.	O

Solution	O
was	O
frequently	O
mixed	O
using	O
vortex	O
mixer	O
.	O

Supernatant	O
was	O
removed	O
and	O
saved	O
after	O
appropriate	O
labelling	O
.	O

Gel	O
-	O
slices	O
were	O
then	O
incubated	O
with	O
100	O
μl	O
of	O
50	O
%	O
ACN	O
/	O
5	O
%	O
TFA	O
at	O
37	O
°	O
C	O
for	O
60	O
minutes	O
to	O
extract	O
the	O
peptides	O
from	O
gel	O
-	O
slices	O
.	O

Supernatant	O
was	O
collected	O
and	O
pooled	O
with	O
earlier	O
collected	O
supernatant	O
.	O

Supernatant	O
was	O
then	O
concentrated	O
at	O
room	O
temperature	O
until	O
moderate	O
dryness	O
.	O

Dried	O
peptides	O
were	O
dissolved	O
in	O
5	O
μl	O
of	O
0	O
.	O
1	O
%	O
TFA	O
/	O
HPLC	O
Water	O
solution	O
and	O
set	O
-	O
aside	O
for	O
mass	O
-	O
spectrometry	O
analysis	O
.	O

HPLC	O
-	O
CHIP	O
-	O
MS	O

Refer	O
supplementary	O
information	O
.	O

Spectra	O
Analysis	O
and	O
Protein	O
Database	O
Searches	O

Agilent	O
Mass	O
Hunter	O
software	O
was	O
used	O
for	O
data	O
acquisition	O
and	O
analysis	O
of	O
Total	O
ion	O
chromatograms	O
.	O

Protein	O
searches	O
were	O
carried	O
out	O
using	O
Morpheus	O
software	O
tools	O
using	O
the	O
Human	B-OG
proteome	O
database	O
.	O

Auto	O
-	O
validation	O
protocol	O
having	O
<	O
1	O
%	O
False	O
Detection	O
Rate	O
was	O
used	O
in	O
confirming	O
the	O
identity	O
of	O
protein	O
.	O

The	O
peptide	O
sequence	O
was	O
also	O
analysed	O
for	O
variable	O
modifications	O
such	O
as	O
methionine	O
oxidation	O
,	O
acetylation	O
,	O
cysteine	O
sulfoxide	O
,	O
deamidation	O
and	O
pyro	O
glutamic	O
acid	O
modification	O
.	O

Molecular	O
docking	O

Molecular	O
docking	O
was	O
performed	O
using	O
Molecular	O
Operating	O
Environment	O
(	O
MOE	O
)	O
version	O
2014	O
.	O
0901	O
,	O
Chemical	O
Computing	O
Group	O
Inc	O
.,	O
Montreal	O
,	O
Canada45	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
Histone	B-GP
deacetylase	I-GP
2	I-GP
(	O
HDAC2	B-GP
)	O
was	O
obtained	O
from	O
Protein	O
Data	O
bank	O
(	O
PDB	O
).	O

The	O
PDB	O
ID	O
of	O
the	O
protein	O
is	O
4LY1	O
,	O
this	O
crystal	O
structure	O
is	O
chosen	O
as	O
this	O
is	O
having	O
the	O
best	O
resolution	O
(	O
1	O
.	O
57	O
Å	O
)	O
among	O
all	O
HDAC2	B-GP
crystal	O
structures	O
.	O

The	O
structure	O
was	O
prepared	O
using	O
LigX	O
module	O
of	O
the	O
MOE	O
.	O

This	O
preparation	O
involved	O
addition	O
of	O
hydrogen	O
atoms	O
and	O
addition	O
of	O
any	O
missing	O
residues	O
or	O
atoms	O
.	O

Energy	O
minimization	O
is	O
done	O
using	O
AMBER	O
10	O
:	O
EHT	O
force	O
fields	O
.	O

The	O
3D	O
structure	O
of	O
the	O
compound	O
was	O
constructed	O
using	O
the	O
builder	O
interface	O
of	O
the	O
MOE	O
program	O
.	O

Docking	O
of	O
the	O
compound	O
was	O
done	O
using	O
MOE	O
-	O
DOCK	O
module	O
in	O
MOE	O
.	O

The	O
active	O
site	O
of	O
the	O
target	O
protein	O
is	O
defined	O
by	O
the	O
inhibitor	O
present	O
in	O
the	O
crystal	O
structure	O
.	O

Triangle	O
matcher	O
is	O
used	O
as	O
the	O
placement	O
methodology	O
and	O
London	O
dG	O
is	O
used	O
as	O
a	O
scoring	O
methodology	O
.	O

The	O
best	O
pose	O
was	O
selected	O
on	O
the	O
basis	O
of	O
the	O
best	O
score	O
.	O

Additional	O
Information	O

How	O
to	O
cite	O
this	O
article	O
:	O
Hati	O
,	O
S	O
.	O
et	O
al	O
.	O
Spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
as	O
potent	O
anti	O
-	O
breast	B-DS
cancer	I-DS
compounds	O
:	O
Their	O
design	O
,	O
synthesis	O
,	O
biological	O
evaluation	O
and	O
cellular	O
target	O
identification	O
.	O
Sci	O
.	O

Rep	O
.	O
6	O
,	O
32213	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
srep32213	O
(	O
2016	O
).	O

Supplementary	O
Material	O

Supplementary	O
Information	O

Author	O
Contributions	O
S	O
.	O
H	O
.	O
and	O
P	O
.	O
K	O
.	O
D	O
.	O
conducted	O
the	O
chemical	O
synthesis	O
and	O
S	O
.	O
T	O
.	O
conducted	O
the	O
biological	O
screening	O
.	O

R	O
.	O
A	O
.	O
conducted	O
the	O
molecular	O
docking	O
.	O

S	O
.	O
S	O
.	O
and	O
A	O
.	O
S	O
.	O
planned	O
the	O
biological	O
and	O
docking	O
experiments	O
respectively	O
.	O

R	O
.	O
S	O
.	O
conducted	O
the	O
protein	O
deconvolution	O
experiment	O
.	O

S	O
.	O

Sen	O
.	O
conceived	O
and	O
planned	O
the	O
project	O
and	O
wrote	O
the	O
manuscript	O
.	O

Representative	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
natural	O
and	O
non	O
-	O
natural	O
bioactive	O
compounds	O
,	O
Spirotryptostatin	O
A	O
(	O
1	O
)	O
(	O
inhibits	O
tubulin	O
polymerization	O
),	O
Spirotryptostatin	O
B	O
(	O
2	O
)	O
(	O
inhibits	O
cancer	O
cells	O
at	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
)	O
and	O
MI	O
-	O
5	O
(	O
3	O
)	O
(	O
inhibits	O
p53	O
-	O
MDM2	O
protein	O
-	O
protein	O
interaction	O
).	O

One	O
of	O
the	O
resulting	O
compounds	O
5	O
,	O
inhibits	O
proliferation	O
of	O
MCF	O
-	O
7	O
cells	O
and	O
the	O
putative	O
binding	O
targets	O
are	O
HDAC2	O
and	O
prohibitin	O
2	O
.	O

The	O
new	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
scaffold	O
based	O
compounds	O
,	O
5a	O
–	O
o	O
and	O
other	O
analogs	O
were	O
designed	O
by	O
drawing	O
inspiration	O
from	O
natural	O
products	O
such	O
as	O
Chaetocochins	O
G	O
,	O
compound	O
4	O
and	O
Vinorelbine	O
.	O

Synthesis	O
of	O
a	O
library	O
of	O
spiro	O
[	O
pyrrolidine	O
-	O
3	O
,	O
3	O
´-	O
oxindole	O
]	O
compounds	O
5b	O
–	O
o	O
via	O
one	O
pot	O
Pictet	O
Spengler	O
-	O
oxidative	O
ring	O
contraction	O
of	O
tryptamine	O
at	O
room	O
temperature	O
with	O
variety	O
of	O
aromatic	O
aldehydes	O
were	O
executed	O
.	O

The	O
retention	O
characteristics	O
of	O
5l	O
on	O
the	O
nitrocellulose	O
matrix	O
is	O
shown	O
above	O
.	O

HPLC	O
-	O
UV	O
based	O
method	O
indicated	O
43	O
%	O
of	O
5l	O
got	O
immobilized	O
on	O
the	O
matrix	O
.	O

(	O
A	O
)	O
3D	O
surface	O
representation	O
of	O
HDAC2	O
is	O
depicted	O
,	O
green	O
color	O
represents	O
the	O
active	O
site	O
residues	O
with	O
which	O
our	O
compound	O
is	O
binding	O
.	O

(	O
B	O
)	O
Stick	O
model	O
represents	O
the	O
binding	O
of	O
5l	O
with	O
active	O
site	O
residues	O
.	O

Entry	O

Compound	O

Percentage	O
inhibitiona	O

EC50	O
(	O
μM	O
)	O
b	O

MCF	O
-	O
7	O

COS	O
-	O
7	O

MCF10A	O

MCF	O
-	O
7	O

1	O

5a	O

35	O
.	O
06	O
±	O
0	O
.	O
09	O

11	O
.	O
73	O
±	O
0	O
.	O
09	O

−	O

−	O

2	O

5b	O

33	O
.	O
10	O
±	O
0	O
.	O
12	O

20	O
.	O
73	O
±	O
0	O
.	O
11	O

−	O

−	O

3	O

5c	O

34	O
.	O
46	O
±	O
0	O
.	O
11	O

28	O
.	O
80	O
±	O
0	O
.	O
13	O

−	O

−	O

4	O

5d	O

44	O
.	O
25	O
±	O
0	O
.	O
17	O

9	O
.	O
22	O
±	O
0	O
.	O
12	O

−	O

−	O

5	O

5e	O

54	O
.	O
67	O
±	O
0	O
.	O
08	O
*	O

3	O
.	O
56	O
±	O
0	O
.	O
19	O
*	O

4	O
.	O
48	O

6	O
.	O
00	O
*	O

6	O

5f	O

38	O
.	O
48	O
±	O
0	O
.	O
18	O

34	O
.	O
87	O
±	O
0	O
.	O
17	O

−	O

−	O

7	O

5g	O

25	O
.	O
29	O
±	O
0	O
.	O
24	O

2	O
.	O
39	O
±	O
0	O
.	O
23	O

−	O

−	O

8	O

5h	O

50	O
.	O
62	O
±	O
0	O
.	O
24	O

25	O
.	O
20	O
±	O
0	O
.	O
06	O

−	O

−	O

9	O

5i	O

53	O
.	O
66	O
±	O
0	O
.	O
06	O
*	O

15	O
.	O
60	O
±	O
0	O
.	O
09	O
*	O

0	O
.	O
8	O

4	O
.	O
01	O
*	O

10	O

5j	O

38	O
.	O
72	O
±	O
0	O
.	O
15	O

7	O
.	O
52	O
±	O
0	O
.	O
15	O

−	O

−	O

11	O

5k	O

44	O
.	O
40	O
±	O
0	O
.	O
09	O

7	O
.	O
14	O
±	O
0	O
.	O
19	O

−	O

−	O

12	O

5l	O

60	O
.	O
96	O
±	O
0	O
.	O
09	O
*	O

15	O
.	O
42	O
±	O
0	O
.	O
18	O
*	O

0	O
.	O
08	O

3	O
.	O
53	O
*	O

13	O

5m	O

31	O
.	O
81	O
±	O
0	O
.	O
11	O

−	O
0	O
.	O
51	O
±	O
0	O
.	O
29	O

−	O

−	O

14	O

Etoposide	O

71	O
.	O
95	O
±	O
0	O
.	O
11	O

77	O
.	O
65	O
±	O
0	O
.	O
10	O

−	O

−	O

Entry	O

UniProt	O
ID	O

Protein	O
Description	O

Protein	O
Class	O

1	O

Q92769	O

Histone	O
deacetylase	O
2	O
(	O
HDAC2	O
)	O

Nuclear	O
Protein	O
/	O
Enzyme	O

2	O

Q99623	O

Prohibitin	O
2	O

Structural	O

3	O

Q9P2E9	O

Ribosome	O
-	O
binding	O
protein	O
1	O

Receptor	O

4	O

Q08J23	O

tRNA	O
(	O
cytosine	O
(	O
34	O
)-	O
C	O
(	O
5	O
))-	O
methyltransferase	O

Enzyme	O

5	O

Q5JTZ9	O

Alanine	O
—	O
tRNA	O
ligase	O
,	O
mitochondrial	O

Enzyme	O

6	O

Q13423	O

NAD	O
(	O
P	O
)	O
transhydrogenase	O
,	O
mitochondrial	O

Enzyme	O

7	O

Q9NQC3	O

Reticulon	O
-	O
4	O

Growth	O
Factor	O

